Synlogic Announces Appointment of General Counsel and Corporate Secretary
CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Brendan St. Amant as General Counsel and Corporate Secretary effective July 1, 2022.
“Since joining Synlogic last year, Brendan has been invaluable in his guidance and sound counsel on many complex legal and business issues,” said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. “In his new role, Brendan will continue to provide strong leadership as the company continues its progress towards many important clinical and regulatory milestones.”
Brendan joined Synlogic in 2021 as Vice President, Head of Legal. Prior to joining Synlogic, he was Vice President, Legal, and member of the leadership team at Ohana Biosciences and was senior counsel at Vertex Pharmaceuticals. Brendan was previously an associate and partner at the law firm of Donnelly, Conroy & Gelhaar, LLP, in Boston where he focused on commercial controversies and government enforcement. Earlier in his legal career, Brendan served as a clerk for the U.S. District Court for the District of Connecticut and was an associate at the law firm of Goodwin Procter. He received his B.A. in History from Cornell University, J.D. from Harvard Law School, and his M.P.P from the Harvard Kennedy School. Brendan has served on several practice-related bar committees and on the executive committee of the Board of Trustees of the Massachusetts Continuing Legal Education corporation.
About Synlogic
Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic’s reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. In addition to its clinical programs, Synlogic has research collaborations with Roche on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease and with Ginkgo Bioworks on additional undisclosed preclinical assets. For additional information visit .
Media Contact:
Bill Berry
Berry & Company Public Relations
212-253-8881;
Investor Contact:
Andrew Funderburk
Kendall Investor Relations
617-914-0008;
